Drug intelligence / Profile preview

SYN-017

Development stage: Preclinical
Lead developer: Synosia

Overview

SYN-017 was a clinical-stage drug candidate developed by Synosia Therapeutics for the treatment of depression. It was part of Synosia's pipeline that was acquired by Biotie Therapies in an all-stock transaction. Specific details regarding its mechanism of action or modality are not publicly available from the provided context.

Beyond the preview

Go deeper on SYN-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYN-017.

Explore the full profile